STADA Arzneimittel Overview
- Year Founded
-
1895
- Status
-
Public
- Employees
-
13,183
- Investments
-
40
- Share Price
-
$110.42
- (As of Friday Closing)
STADA Arzneimittel General Information
Description
Manufacturer of prescription generics and over-the-counter medicine intended to serve the healthcare and pharmaceutical markets. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharmaceuticals, thereby ensuring that the everyday health of patients remains affordable.
Contact Information
Website
www.stada.comCorporate Office
- Stadastraße 2-18
- 61118 Bad Vilbel
- Germany
Corporate Office
- Stadastraße 2-18
- 61118 Bad Vilbel
- Germany
STADA Arzneimittel Timeline
STADA Arzneimittel Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $110.42 | $115.00 | $75.15 - $115.00 | $7.42B | 62.3M | 333.33 |
STADA Arzneimittel Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| Revenue | 4,041,335 | 4,041,335 | 3,992,395 | 3,841,821 |
| EBITDA | 867,824 | 867,824 | 855,260 | 812,535 |
| Net Income | 351,709 | 291,956 | ||
| Total Assets | 6,171,995 | 6,518,133 | ||
| Total Debt | 2,902,823 | 3,515,108 |
STADA Arzneimittel Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
STADA Arzneimittel Comparisons
Industry
Financing
Details
000000
000-00
STADA Arzneimittel Competitors (45)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbott India | Corporation | Mumbai, India | 0000 | 00000000 | ||
| DSM-Firmenich | Corporation | Kaiseraugst, Switzerland | 00000 | 00000 | 000000000 | 00000 |
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria | 00 | 00000000 | ||
| Phibro Animal Health | Formerly PE-Backed | Teaneck, NJ | 0000 | 00.000 | 000000000 - | 00.000 |
| Eisai | Corporation | Tokyo, Japan | 00000 | 0000 |
STADA Arzneimittel Patents
STADA Arzneimittel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4424303-A1 | Lenvatinib composition with improved bioavailability | Pending | 28-Feb-2023 | ||
| EP-4252737-A1 | Sunscreen composition for protecting the skin from visible light | Pending | 30-Mar-2022 | 0000000000 | 00 |
| EP-4249015-A1 | Method for preparing a sterilised drug delivery device | Pending | 25-Mar-2022 | 000000000 | 0 |
| EP-4046626-A1 | Use of a pemetrexed concentrate solution | Pending | 21-Feb-2021 | 0000000000 | 0 |
| EP-4294365-A1 | Use of a pemetrexed concentrate solution | Pending | 21-Feb-2021 | A61K9/0019 |
STADA Arzneimittel Executive Team (27)
| Name | Title | Board Seat |
|---|---|---|
| Peter Goldschmidt | Chief Executive Officer & Chairman of the Executive Board | |
| Boris Doebler | Chief Financial Officer | |
| Miguel Fernandez Ph.D | Chief Technical Officer | |
| Simone Berger | Chief People Officer | |
| Markus Damm | Deputy Chairman of the Advisory Board & Director, IT and Finance Transformation |
STADA Arzneimittel Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0ü0000 00 00.0 | STADA Arzneimittel | Chairman of the Supervisory Board | 000 0000 |
| 000-0000000 00000 | Cinven | Board Member | 000 0000 |
| 00000 00000000000 | STADA Arzneimittel | Chief Executive Officer & Chairman of the Executive Board | 000 0000 |
STADA Arzneimittel Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
STADA Arzneimittel Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
STADA Arzneimittel Investments & Acquisitions (40)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sanofi (Healthcare Brands) | 12-Jul-2023 | 0000000000 | Pharmaceuticals | 00000 000 | |
| Nemus Lex | 23-Dec-2022 | 0000000000 | Personal Products | ||
| Sanofi (16 Consumer Healthcare Brands) | 28-Jun-2021 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| Lobsor Pharmaceuticals | 01-Sep-2020 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| GlaxoSmithKline (15 consumer health brands) | 12-Jun-2020 | Corporate Asset Purchase | 00000 | Buildings and Property | 00000 000 |
STADA Arzneimittel Subsidiaries (10)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Lobsor Pharmaceuticals | Pharmaceuticals | Uppsala, Sweden | 2013 |
| Nemus Lex | Personal Products | Zagreb, Croatia | 0000 |
| Walmark | Pharmaceuticals | Trinec, Czech Republic | 0000 |
| Aliud Pharma | Pharmaceuticals | Laichingen, Germany | 0000 |
| Croma-Pharma | Pharmaceuticals | Leobendorf, Austria | 0000 |
STADA Arzneimittel ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
18.09 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
STADA Arzneimittel Exits (8)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pymepharco | 01-Jan-2013 | 000000000000 | Completed |
|
|
| Pymepharco | 01-Jan-2010 | 000000000 | 0000 | Completed |
|
| Pymepharco | 01-Jan-2008 | 000000000 | 00.000 | Completed |
|
| LipoNova | 26-Feb-2004 | 000000000 | 00.000 | Completed |
|
| Sirton Pharmaceuticals | 17-May-2002 | Merger/Acquisition | Completed |
STADA Arzneimittel FAQs
-
When was STADA Arzneimittel founded?
STADA Arzneimittel was founded in 1895.
-
Who is the CEO of STADA Arzneimittel?
Peter Goldschmidt is the CEO of STADA Arzneimittel.
-
Where is STADA Arzneimittel headquartered?
STADA Arzneimittel is headquartered in Bad Vilbel, Germany.
-
What is the size of STADA Arzneimittel?
STADA Arzneimittel has 13,183 total employees.
-
What industry is STADA Arzneimittel in?
STADA Arzneimittel’s primary industry is Pharmaceuticals.
-
Is STADA Arzneimittel a private or public company?
STADA Arzneimittel is a Public company.
-
What is the current stock price of STADA Arzneimittel?
As of 30-Oct-2020 the stock price of STADA Arzneimittel is $110.42.
-
What is the current market cap of STADA Arzneimittel?
The current market capitalization of STADA Arzneimittel is $7.42B.
-
What is STADA Arzneimittel’s current revenue?
The trailing twelve month revenue for STADA Arzneimittel is $4.04B.
-
Who are STADA Arzneimittel’s competitors?
Abbott India, DSM-Firmenich, GlaxoSmithKline Consumer Nigeria, Phibro Animal Health, and Eisai are some of the 45 competitors of STADA Arzneimittel.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
